BioWorld

Feb. 4, 2002

View Archived Issues

ZymoGenetics Raises $120M In Year’s First Biotech IPO

Read More

Discovering Relaxin Hormone’s Two Too-Long-AWOL Receptors Renews Interest In Its Roles

Read More

Pozen Starts Phase III Of MT 300 For Treating Severe Migraine

Read More

Biogen, Genaissance Align In Pharmacogenomics Area

Read More

Chiron Licenses TB Product To Public-Private Partnership

Read More

Other News To Note

Read More

Amgen Gains Quick Approval For Next-Generation Neupogen

Following swift approval from the FDA, Amgen Inc. expects its next blockbuster drug for chemotherapy patients to enter the market April 1. (BioWorld Today) Read More